Skip to main content
. 2021 Apr 15;11(13):6315–6333. doi: 10.7150/thno.52843

Figure 8.

Figure 8

The circUbe3a/miR-138-5p/RhoC axis regulates CF function in vitro. A: Representative Western blot results from three independent experiments and quantification of RhoC expression in CFs treated with LV-RhoC or si-RhoC (*P < 0.05 versus the Ctrl group; #P < 0.05 versus the LV-RhoC group; n = 3 per group). B: FCM indicated that RhoC was positively associated with cell cycle progression in CFs. (*P < 0.05 versus the Ctrl group; #P < 0.05 versus the LV-RhoC group; n = 3 per group). C: A transwell assay was performed to assess CF migration after treatment with LV-RhoC or LV-siRNA-RhoC.(*P < 0.05 versus the Ctrl group; #P < 0.05 versus the LV-RhoC group; n = 3 per group). D: Representative Western blot results from three independent experiments and quantification of collagen I, collagen III, and α-SMA expression in CFs treated with LV-RhoC or LV-siRNA-RhoC (*P < 0.05 versus the Ctrl group; #P < 0.05 versus the LV-RhoC group; n = 3 per group). E: Representative Western blot results from three independent experiments and quantification of collagen I, collagen III, and α-SMA expression in CFs treated with circUbe3a, circUbe3a+mimics, and circUbe3a +mimics+RhoC (*P < 0.05 versus the Ctrl group; #P < 0.05 versus the circUbe3a group; &P < 0.05 versus the circUbe3a + mimics group;n = 3 per group). F: Representative Western blot results from three independent experiments and quantification of RhoC expression in CFs treated with circUbe3a, circUbe3a+mimics, circUbe3a + mimics + RhoC (*P < 0.05 versus the Ctrl group; #P < 0.05 versus the circUbe3a group; &P < 0.05 versus the circUbe3a + mimics group; n = 3 per group). G: Representative Western blot results from three independent experiments and quantification of RhoC expression in CFs treated with circUbe3a, circUbe3a + mimics, M2-SEVs, and M2-SEVs + mimics (*P < 0.05 versus the Ctrl group; #P < 0.05 versus the LV-circUbe3a group; &P < 0.05 versus the M2-SEVs group; n = 3 per group).